Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.
Drug company Eli Lilly announced it will cut the price of its insulin by 70 percent. How much will the drug cost and what does this mean for people with diabetes? Here's everything you need to ...
Grinding pancreases for insulin at Eli Lilly and Company, early 1930s ... introduced standardized strengths and developed new long-acting insulins. Although not identical to human insulin, ...
A settlement with drug-maker Novo Nordisk resolves the state's years-long litigation over insulin pricing and follows similar settlements already reached with Eli Lilly and Sanofi. “In 2018 ...
Tandem Diabetes Care TNDM has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly’s ultra-rapid acting ... near and long term, ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
The Chairman and Managing Director of Eli Lilly ... of Eli Lilly and Co., India, disclosed on January 3rd, during the announcement of a price cut in the company's human insulin product ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...